Rani Therapeutics Inc. (RANI)
Company Description
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics.
The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing.
Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.
The company was incorporated in 2012 and is headquartered in San Jose, California.
| Country | United States |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Talat Imran |
Contact Details
Address: 2051 Ringwood Avenue San Jose, California United States | |
| Website | https://www.ranitherapeutics.com |
Stock Details
| Ticker Symbol | RANI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001856725 |
| CUSIP Number | 753018100 |
| ISIN Number | US7530181004 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Talat Imran | Chief Executive Officer & Director |
| Svai S. Sanford | Chief Financial Officer |
| Alireza Javadi | Vice President of Technical Operations |
| Arvinder Dhalla | Vice President of Clinical Development |
| Bella Vazquez | Vice President of Human Resources |
| Dr. Mir Hashim | Chief Scientific Officer |
| Eric Groen J.D. | General Counsel |
| Kate McKinley M.B.A. | Chief Business Officer |
| Mir A. Imran | Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | DEFA14A | Filing |
| Apr 30, 2025 | 8-K | Current Report |
| Apr 16, 2025 | ARS | Filing |
| Apr 16, 2025 | DEFA14A | Filing |
| Apr 16, 2025 | DEF 14A | Filing |
| Apr 09, 2025 | 8-K | Current Report |
| Mar 31, 2025 | S-8 | Filing |
| Mar 31, 2025 | 10-K | Annual Report |
| Mar 31, 2025 | 8-K | Current Report |
| Dec 17, 2024 | 4 | Filing |